跳至主要内容
临床试验/JPRN-UMIN000013316
JPRN-UMIN000013316已完成2 期

Randomized phase II trial evaluating the efficacy and safety of standard care +/- continuous gefitinib treatment beyond progression in patients with advanced NSCLC after 1st line treatment with gefitinib(TORG1019) - Continuous gefitinib beyond PD study(TORG1319)

Thoracic Oncology Research Group0 个研究点目标入组 70 人开始时间: 2014年3月3日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 74years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Treated by other molecular targeted drug or cytotoxic agent 2) Prior radiation for primary lesions 3) History of steroid therapy for radiation pneumonitis 4) Patients with symptomatic brain metastasis 5) Interstitial pneumonitis or pulmonary fibrosis detectable on CT scan 6) Patient with pleural effusion, pericardial effusion, ascites or superior vena cave 7) With active infection or other serious medical complications 8) Clinically significant allergy 9) With active double cancer 10) Pregnancy or lactating patients 11) Judged to be not suitable by the attending physician

研究者

发起方
Thoracic Oncology Research Group

相似试验